Tag: CX 2026
“We have to do more to help people achieve the technical...
High-profile venous specialists discuss developments in pulmonary embolism (PE) treatment space during CX 2026, touching on the HI-PEITHO, STORM-PE, PEERLESS and PEERLESS 2 trials....
The burgeoning PE care landscape: “From no data to a lot...
Patrick Muck (Good Samaritan Hospital, Cincinnati, USA) is joined in the CX Studio by David Dexter (Sentara Vascular Specialists, Norfolk, USA), Steven Abramowitz (MedStar...
The role of open venous surgery as endovascular interventions fail
Manj Gohel (Cambridge University Hospitals, Cambridge, UK) underscores the importance of retaining open venous surgical skills in the endovascular era. Watch the full interview...
The enduring importance of open venous surgery: “We have to retain...
"I think it's going to be a growing problem, particularly as we see a greater number of people with—unfortunately—failed endovascular treatments." Those were the...
Venous valve solution: “We’re on the precipice”
David Dexter (Sentara Vascular Specialists, Norfolk, USA) analyses the state of the replacement venous valve space in the aftermath of the setback that saw...
Venous valves: Where do things stand as endovascular device enters clinical...
David Dexter (Sentara Vascular Specialists, Norfolk, Virginia) speaks to Venous News at CX 2026 following recent faltering steps in a decades-long march toward a...
Invera Medical reports 12-month results from pilot trial of infusion device...
Invera Medical recently announced 12-month results from its pilot clinical study of the Invera infusion device, designed to treat chronic venous disease (CVD). The...
CX 2026: Venous and lymphatic session highlights continued innovation following recent PE trials
“Are we at the end of the road with this technology?” asked attendees of yesterday’s opening venous and lymphatic session at the 2026 Charing...